This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 revenue up 33% and PAT up 49% on strong performance
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue rose 33% to Rs 1,794 crore and PAT climbed 49% to Rs 388 crore. Adjusted EBITDA excluding forex loss grew 47% to Rs 543 crore, with margin up to 30% from 27%. H1 revenue was Rs 3,420 crore, up 29%, and PAT Rs 722 crore, up 40%. US generics and Africa institution sales led growth. Auditor review was unmodified.
Strong growth and wider margins are positive for the stock. Investors should watch US generics momentum and forex swings.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1,794 Cr | ₹1,354 Cr | +32.5% |
| Operating profit | ₹497.8 Cr | ₹281.5 Cr | +76.8% |
| Profit after tax | ₹388.1 Cr | ₹260.2 Cr | +49.2% |
| EBITDA margin | 30.5% | 24.2% | +6.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.